

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

JS-6

**UNITED STATES DISTRICT COURT  
CENTRAL DISTRICT OF CALIFORNIA**

FEDERAL TRADE COMMISSION,  
  
Plaintiff,  
  
v.  
  
REGENERATIVE MEDICAL GROUP,  
INC., a corporation;  
  
TELEHEALTH MEDICAL GROUP, INC.,  
a corporation; and  
  
BRYN JARALD HENDERSON, D.O.,  
individually and as an officer of  
REGENERATIVE MEDICAL  
GROUP, INC. and TELEHEALTH  
MEDICAL GROUP, INC.,  
  
Defendants.

Case No. 8:18-cv-01838-AG-KES

**ORDER ON STIPULATION  
FOR PERMANENT  
INJUNCTION AND  
MONETARY JUDGMENT**

1 Plaintiff, the Federal Trade Commission (“Commission”), filed its  
2 Complaint for a permanent injunction and other equitable relief in this matter,  
3 pursuant to Section 13(b) of the Federal Trade Commission Act (“FTC Act”), 15  
4 U.S.C. § 53(b). The Commission and Defendants stipulate to the entry of this  
5 Stipulated Order for Permanent Injunction and Monetary Judgment (“Order”), to  
6 resolve all matters in dispute in this action.

7 **THEREFORE, IT IS ORDERED** as follows:

8 **FINDINGS**

- 9 1. This Court has jurisdiction over this matter.
- 10 2. The Complaint charges that Defendants participated in deceptive and unfair  
11 acts or practices in violation of Sections 5 and 12 of the FTC Act, 15 U.S.C. §§ 45  
12 and 52, in the advertising, marketing, and sale of stem cell therapy to treat, cure,  
13 and mitigate various diseases and health conditions.
- 14 3. Defendants neither admit nor deny any of the allegations in the Complaint,  
15 except as specifically stated in this Order. Only for purposes of this action,  
16 Defendants admit the facts necessary to establish jurisdiction.
- 17 4. Defendants waive any claim that they may have under the Equal Access to  
18 Justice Act, 28 U.S.C. § 2412, concerning the prosecution of this action through  
19 the date of this Order, and agree to bear their own costs and attorney fees.
- 20 5. Defendants and the Commission waive all rights to appeal or otherwise  
21 challenge or contest the validity of this Order.

22 **DEFINITIONS**

23 For the purpose of this Order, the following definitions apply:

- 24 1. **“Covered Product”** means any Dietary Supplement, Food, Drug, or Device.  
25 2. **“Covered Service”** means any health-related service, program, or therapy,  
26 including the Stem Cell Therapy offered by the Regenerative Medical Group, Inc.,  
27 TeleHealth Medical Group, Inc., and their successors and assigns.

1 3. **“Defendants”** means the Individual Defendant and the Corporate  
2 Defendants, individually, collectively, or in any combination.

3 A. **“Corporate Defendants”** means the Regenerative Medical Group,  
4 Inc., the TeleHealth Medical Group, Inc., and their successors and assigns.

5 B. **“Individual Defendant”** means Bryn Jarald Henderson, D.O.

6 4. **“Device”** means an instrument, apparatus, implement, machine, contrivance,  
7 implant, in vitro reagent, or other similar or related article, including any  
8 component, part, or accessory, which is (1) recognized in the official National  
9 Formulary, or the United States Pharmacopeia, or any supplement to them; (2)  
10 intended for use in the diagnosis of disease or other conditions, or in the cure,  
11 mitigation, treatment, or prevention of disease, in humans or other animals; or (3)  
12 intended to affect the structure or any function of the body of humans or other  
13 animals; and which does not achieve any of its principal intended purposes through  
14 chemical action within or on the body of humans or other animals and which is not  
15 dependent upon being metabolized for the achievement of any of its principal  
16 intended purposes.

17 5. **“Dietary Supplement”** means (1) any product labeled as a dietary  
18 supplement or otherwise represented as a dietary supplement; or (2) any pill, tablet,  
19 capsule, powder, softgel, gelcap, liquid, or other similar form containing one or  
20 more ingredients that are a vitamin, mineral, herb or other botanical, amino acid,  
21 probiotic, or other dietary substance for use by humans to supplement the diet by  
22 increasing the total dietary intake, or a concentrate, metabolite, constituent, extract,  
23 or combination of any ingredient described above, that is intended to be ingested,  
24 and is not represented to be used as a conventional food or as a sole item of a meal  
25 or the diet.

26 6. **“Drug”** means (1) articles recognized in the official United States  
27 Pharmacopoeia, official Homoeopathic Pharmacopoeia of the United States, or  
28 official National Formulary, or any supplement to any of them; (2) articles

1 intended for use in the diagnosis, cure, mitigation, treatment, or prevention of  
2 disease in humans or other animals; (3) articles (other than food) intended to affect  
3 the structure or any function of the body of humans or other animals; and (4)  
4 articles intended for use as a component of any article specified in (1), (2), or (3);  
5 but does not include devices or their components, parts, or accessories.

6 7. **“Essentially Equivalent Product”** means a product that contains the  
7 identical ingredients, except for inactive ingredients (e.g., binders, colors, fillers,  
8 excipients) in the same form and dosage, and with the same route of administration  
9 (e.g., orally, sublingually), as the Covered Product; provided that the Covered  
10 Product may contain additional ingredients if reliable scientific evidence generally  
11 accepted by experts in the field indicates that the amount and combination of  
12 additional ingredients is unlikely to impede or inhibit the effectiveness of the  
13 ingredients in the Essentially Equivalent Product.

14 8. **“Food”** means (1) any article used for food or drink for humans or other  
15 animals; (2) chewing gum; and (3) any article used for components of any such  
16 article.

17 9. **“Including”** means including but not limited to.

18 10. **“Stem Cell Therapy”** means any therapy that uses stem cells, including  
19 stem cells derived from amniotic fluid, amniotic membrane, adipose tissue, bone  
20 marrow, umbilical cord blood, and peripheral blood.

21 **ORDER**

22 **I.**

23 **PROHIBITED REPRESENTATIONS:**

24 **HEALTH-RELATED CLAIMS REQUIRING**

25 **HUMAN CLINICAL TESTING FOR SUBSTANTIATION**

26 **IT IS ORDERED** that Defendants, Defendants’ officers, agents, and  
27 employees, and all other persons in active concert or participation with any of  
28

1 them, who receive actual notice of this Order, whether acting directly or indirectly,  
2 in connection with the manufacturing, labeling, advertising, promotion, offering  
3 for sale, sale, or distribution of any Covered Product or Covered Service, are  
4 permanently restrained and enjoined from making, or assisting others in making,  
5 expressly or by implication, including through the use of a product or service  
6 name, endorsement, depiction, or illustration, any representation that such product  
7 or service:

8       A. Cures, mitigates, or treats any disease or health condition, including  
9 Parkinson's disease, autism, multiple sclerosis, cerebral palsy, traumatic brain  
10 injury, heart disease, macular degeneration, chronic kidney disease, osteoarthritis,  
11 and stroke; or

12       B. Is comparable or superior to conventional medical treatments in  
13 curing, mitigating, or treating any disease or health condition;  
14 unless the representation is non-misleading, and, at the time of making such  
15 representation, they possess and rely upon competent and reliable scientific  
16 evidence substantiating that the representation is true. For purposes of this  
17 Section, competent and reliable scientific evidence shall consist of human clinical  
18 testing of the Covered Product or Covered Service or, in the case of a food, drug,  
19 or dietary supplement, of the Covered Product or of an Essentially Equivalent  
20 Product, that is sufficient in quality and quantity based on standards generally  
21 accepted by experts in the relevant disease, condition, or function to which the  
22 representation relates, when considered in light of the entire body of relevant and  
23 reliable scientific evidence, to substantiate that the representation is true. Such  
24 testing must be: (1) randomized, double-blind, and placebo-controlled; and (2)  
25 conducted by researchers qualified by training and experience to conduct such  
26 testing. In addition, all underlying or supporting data and documents generally  
27 accepted by experts in the field as relevant to an assessment of such testing as  
28 described in the Section entitled Preservation of Records Relating to Competent

1 and Reliable Human Clinical Tests or Studies must be available for inspection and  
2 production to the Commission. Persons covered by this Section have the burden of  
3 proving that a product satisfies the definition of Essentially Equivalent Product.

4 **II.**

5 **PROHIBITED REPRESENTATIONS:**  
6 **OTHER HEALTH-RELATED CLAIMS**

7 **IT IS FURTHER ORDERED** that Defendants, Defendants' officers,  
8 agents, and employees, and all other persons in active concert or participation with  
9 any of them, who receive actual notice of this Order, whether acting directly or  
10 indirectly, in connection with the manufacturing, labeling, advertising, promotion,  
11 offering for sale, sale, or distribution of any Covered Product or Covered Service,  
12 are permanently restrained and enjoined from making, or assisting others in  
13 making, expressly or by implication, including through the use of a product or  
14 service name, endorsement, depiction, or illustration, any representation, other than  
15 representations covered under the Section of this Order entitled Prohibited  
16 Representations: Health-Related Claims Requiring Human Clinical Testing for  
17 Substantiation, about the health benefits, performance, efficacy, safety, or side  
18 effects of any Covered Product or Covered Service, unless the representation is  
19 non-misleading, and, at the time of making such representation, they possess and  
20 rely upon competent and reliable scientific evidence that is sufficient in quality and  
21 quantity based on standards generally accepted by experts in the relevant disease,  
22 condition, or function to which the representation relates, when considered in light  
23 of the entire body of relevant and reliable scientific evidence, to substantiate that  
24 the representation is true.

25  
26 For purposes of this Section, competent and reliable scientific evidence  
27 means tests, analyses, research, or studies (1) that have been conducted and  
28 evaluated in an objective manner by experts in the relevant disease, condition, or

1 function to which the representation relates; (2) that are generally accepted by such  
2 experts to yield accurate and reliable results; and (3) that are randomized, double-  
3 blind, and placebo-controlled human clinical testing of the Covered Product or  
4 Covered Service or, in the case of a food, drug, or dietary supplement, of the  
5 Covered Product or of an Essentially Equivalent Product, when such experts would  
6 generally require such human clinical testing to substantiate that the representation  
7 is true. In addition, when such tests or studies are human clinical tests or studies,  
8 all underlying or supporting data and documents generally accepted by experts in  
9 the field as relevant to an assessment of such testing as set forth in the Section  
10 entitled Preservation of Records Relating to Competent and Reliable Human  
11 Clinical Tests or Studies must be available for inspection and production to the  
12 Commission. Persons covered by this Section have the burden of proving that a  
13 product satisfies the definition of Essentially Equivalent Product.

14 **III.**

15 **FDA-APPROVED CLAIMS**

16 **IT IS FURTHER ORDERED** that nothing in this Order prohibits  
17 Defendants, Defendants' officers, agents, and employees, or all other persons in  
18 active concert or participation with any of them from:

19 A. For any drug, making a representation that is approved in labeling for  
20 such drug under any tentative final or final monograph promulgated by the Food  
21 and Drug Administration, or under any new drug application approved by the Food  
22 and Drug Administration; and

23 B. For any product, making a representation that is specifically  
24 authorized for use in labeling for such product by regulations promulgated by the  
25 Food and Drug Administration pursuant to the Nutrition Labeling and Education  
26 Act of 1990 or permitted under Sections 303-304 of the Food and Drug  
27 Administration Modernization Act of 1997.

1 IV.

2 PRESERVATION OF RECORDS RELATING TO  
3 COMPETENT AND RELIABLE HUMAN CLINICAL TESTS OR STUDIES

4 IT IS FURTHER ORDERED that, with regard to any human clinical test  
5 or study (“test”) upon which Defendants rely to substantiate any claim covered by  
6 this Order, Defendants shall secure and preserve all underlying or supporting data  
7 and documents generally accepted by experts in the field as relevant to an  
8 assessment of the test, including:

9 A. All protocols and protocol amendments, reports, articles, write-ups, or  
10 other accounts of the results of the test, and drafts of such documents reviewed by  
11 the test sponsor or any other person not employed by the research entity;

12 B. All documents referring or relating to recruitment; randomization;  
13 instructions, including oral instructions, to participants; and participant  
14 compliance;

15 C. Documents sufficient to identify all test participants, including any  
16 participants who did not complete the test, and all communications with any  
17 participants relating to the test; all raw data collected from participants enrolled in  
18 the test, including any participants who did not complete the test; source  
19 documents for such data; any data dictionaries; and any case report forms;

20 D. All documents referring or relating to any statistical analysis of any  
21 test data, including any pretest analysis, intent-to-treat analysis, or between-group  
22 analysis performed on any test data; and

23 E. All documents referring or relating to the sponsorship of the test,  
24 including all communications and contracts between any sponsor and the test’s  
25 researchers.

26 *Provided, however,* the preceding preservation requirement does not apply to  
27 a reliably reported test, unless the test was conducted, controlled, or sponsored, in  
28 whole or in part by: (1) any Defendant; (2) any Defendant’s officers, agents,

1 representatives, or employees; (3) any other person or entity in active concert or  
2 participation with any Defendant; (4) any person or entity affiliated with or acting  
3 on behalf of any Defendant; (5) any supplier of any ingredient contained in the  
4 product at issue to any of the foregoing or to the product's manufacturer; or (6) the  
5 supplier or manufacturer of such product.

6 For purposes of this Section, "reliably reported test" means a report of the  
7 test has been published in a peer-reviewed journal, and such published report  
8 provides sufficient information about the test for experts in the relevant field to  
9 assess the reliability of the results.

10 For any test conducted, controlled, or sponsored, in whole or in part, by  
11 Defendants, Defendants must establish and maintain reasonable procedures to  
12 protect the confidentiality, security, and integrity of any personal information  
13 collected from or about participants. These procedures must be documented in  
14 writing and must contain administrative, technical, and physical safeguards  
15 appropriate to Defendants' size and complexity, the nature and scope of  
16 Defendants' activities, and the sensitivity of the personal information collected  
17 from or about the participants.

18 **V.**

19 **MONETARY JUDGMENT**

20 **IT IS FURTHER ORDERED** that:

21 A. Judgment in the amount of Three Million Three Hundred Ten  
22 Thousand Dollars (\$3,310,000) is entered in favor of the Commission against the  
23 Defendants, jointly and severally, as equitable monetary relief.

24 B. Defendants are ordered to pay to the Commission Five Hundred  
25 Twenty Five Thousand Dollars (\$525,000) as follows:

26 1. One Hundred Seventy Five Thousand Dollars (\$175,000)  
27 within seven (7) days of entry of this Order;

28 2. One Hundred Seventy Five Thousand Dollars (\$175,000)

1 within thirty (30) days of entry of this Order; and

2 3. One Hundred Seventy Five Thousand Dollars (\$175,000)  
3 within sixty (60) days of entry of this Order.

4 C. Such payments must be made by electronic funds transfer in  
5 accordance with instructions previously provided by a representative of the  
6 Commission. Upon payment of the full Five Hundred Twenty Five Thousand  
7 Dollars (\$525,000) pursuant to Subsection B, the remainder of the judgment is  
8 suspended, subject to the Subsections below.

9 D. In the event Defendants fail to pay Five Hundred Twenty Five  
10 Thousand Dollars (\$525,000) within sixty (60) days of entry of this Order,  
11 Defendants shall be in default and the full amount of the judgment shall  
12 immediately become due, plus interest from the date of entry of this judgment  
13 pursuant to 28 U.S.C. § 1961, less any payments already made. *Provided,*  
14 *however,* that in the event of default, the judgment amount set forth in Subsection  
15 A. above shall not become due if the Defendants cure such default within twenty  
16 one (21) calendar days.

17 E. After the expiration of the time to cure the default, the Commission  
18 shall be entitled to immediately exercise any and all rights and remedies against the  
19 Defendants and their property to collect the full amount of the judgment amount  
20 set forth in Subsection A. above and interest thereon, less any payments already  
21 made.

22 F. The Commission's agreement to the suspension of part of the  
23 judgment is expressly premised upon the truthfulness, accuracy, and completeness  
24 of Defendants' sworn financial statements and related documents (collectively,  
25 "financial attestations") submitted to the Commission, namely the:

26 1. Amended Financial Statement of Individual Defendant Bryn  
27 Jarald Henderson signed on July 24, 2018, including the attachments;

28 2. Financial Statement of Corporate Defendant

1 Regenerative Medical Group, Inc. signed by Bryn Jarald Henderson, CEO, on May  
2 16, 2018, including the attachments; and

3 3. Financial Statement of Corporate Defendant TeleHealth  
4 Medical Group, Inc. signed by Bryn Jarald Henderson, CEO, on May 17, 2018,  
5 including the attachments.

6 G. The suspension of the judgment will be lifted as to any Defendant if,  
7 upon motion by the Commission, the Court finds that Defendant failed to disclose  
8 any material asset, materially misstated the value of any asset, or made any other  
9 material misstatement or omission in the financial attestations identified above.

10 H. If the suspension of the judgment is lifted, the judgment becomes  
11 immediately due as to that Defendant in the amount specified in Subsection A.  
12 above (which the parties stipulate only for purposes of this Section represents the  
13 consumer injury alleged in the Complaint), less any payment previously made  
14 pursuant to this Section, plus interest computed from the date of entry of this  
15 Order.

16 **VI.**

17 **ADDITIONAL MONETARY PROVISIONS**

18 A. Defendants relinquish dominion and all legal and equitable right, title,  
19 and interest in all assets transferred pursuant to this Order and may not seek the  
20 return of any assets.

21 B. The facts alleged in the Complaint will be taken as true, without  
22 further proof, in any subsequent civil litigation by or on behalf of the Commission,  
23 including in a proceeding to enforce its rights to any payment or monetary  
24 judgment pursuant to this Order, such as a nondischargeability complaint in any  
25 bankruptcy case.

26 C. The facts alleged in the Complaint establish all elements necessary to  
27 sustain an action by the Commission pursuant to Section 523(a)(2)(A) of the  
28 Bankruptcy Code, 11 U.S.C. § 523(a)(2)(A), and this Order will have collateral

1 estoppel effect for such purposes.

2 D. Defendants acknowledge that their Taxpayer Identification Numbers  
3 (Social Security Numbers or Employer Identification Numbers), which Defendants  
4 previously submitted to the Commission, may be used for collecting and reporting  
5 on any delinquent amount arising out of this Order, in accordance with 31 U.S.C.  
6 §7701.

7 E. All money paid to the Commission pursuant to this Order may be  
8 deposited into a fund administered by the Commission or its designee to be used  
9 for equitable relief, including consumer redress and any attendant expenses for the  
10 administration of any redress fund. If a representative of the Commission decides  
11 that direct redress to consumers is wholly or partially impracticable or money  
12 remains after redress is completed, the Commission may apply any remaining  
13 money for such other equitable relief (including consumer information remedies)  
14 as it determines to be reasonably related to Defendants' practices alleged in the  
15 Complaint. Any money not used for such equitable relief is to be deposited to the  
16 U.S. Treasury as disgorgement. Defendants have no right to challenge any actions  
17 the Commission or its representatives may take pursuant to this Subsection.

18 **VII.**

19 **CUSTOMER INFORMATION**

20 **IT IS FURTHER ORDERED** that Defendants, Defendants' officers,  
21 agents, and employees, and all other persons in active concert or participation with  
22 any of them, who receive actual notice of this Order, are permanently restrained  
23 and enjoined from directly or indirectly:

24 A. failing to provide sufficient customer information, in the form of full  
25 names, addresses, telephone numbers, email addresses, and amounts paid, to  
26 enable the Commission to efficiently administer consumer redress. If a  
27 representative of the Commission requests in writing any information related to  
28

1 redress, Defendants must provide it, in the form prescribed by the Commission,  
2 within 14 days; and

3 B. disclosing, using, or benefitting from customer information, including  
4 the name, address, telephone number, email address, social security number, other  
5 identifying information, or any data that enables access to a customer's account  
6 (including a credit card, bank account, or other financial account), that any  
7 Defendant obtained prior to entry of this Order in connection with the offering of  
8 Stem Cell Therapy.

9 **VIII.**

10 **NOTICE TO PATIENTS**

11 **IT IS FURTHER ORDERED** that, within 30 days of entry of this Order,  
12 Defendants shall send by first-class mail an exact copy of the notice attached as  
13 Attachment A, showing the date of mailing, to any consumer who, as of the date of  
14 entry of this Order:

15 A. Is a patient of the Defendants and has received or will receive Stem  
16 Cell Therapy; or

17 B. Has expressed an interest in scheduling a Stem Cell Therapy  
18 treatment.

19 The notice required by this Section shall not include any other document or  
20 enclosures.

21 **IX.**

22 **ORDER ACKNOWLEDGMENTS**

23 **IT IS FURTHER ORDERED** that Defendants obtain acknowledgments of  
24 receipt of this Order:

25 A. Each Defendant, within 7 days of entry of this Order, must submit to  
26 the Commission an acknowledgment of receipt of this Order sworn under penalty  
27 of perjury.



1 own involvement); (d) describe in detail whether and how that Defendant is in  
2 compliance with each Section of this Order; and (e) provide a copy of each Order  
3 Acknowledgment obtained pursuant to this Order, unless previously submitted to  
4 the Commission.

5           2.       Additionally, Individual Defendant must: (a) identify all  
6 telephone numbers and all physical, postal, email and Internet addresses, including  
7 all residences; (b) identify all business activities, including any business for which  
8 such Defendant performs services whether as an employee or otherwise and any  
9 entity in which such Defendant has any ownership interest; and (c) describe in  
10 detail such Defendant's involvement in each such business, including title, role,  
11 responsibilities, participation, authority, control, and any ownership.

12           B.       For 10 years after entry of this Order, each Defendant must submit a  
13 compliance notice, sworn under penalty of perjury, within 14 days of any change  
14 in the following:

15           1.       Each Defendant must report any change in: (a) any designated  
16 point of contact; or (b) the structure of any Corporate Defendant or any entity that  
17 Defendant has any ownership interest in or controls directly or indirectly that may  
18 affect compliance obligations arising under this Order, including: creation,  
19 merger, sale, or dissolution of the entity or any subsidiary, parent, or affiliate that  
20 engages in any acts or practices subject to this Order.

21           2.       Additionally, Individual Defendant must report any  
22 change in: (a) name, including aliases or fictitious names, or residence address; or  
23 (b) title or role in any business activity, including any business for which such  
24 Defendant performs services whether as an employee or otherwise and any entity  
25 in which such Defendant has any ownership interest, and identify the name,  
26 physical address, and any Internet address of the business or entity.

27

28

1 C. Each Defendant must submit to the Commission notice of the filing of  
2 any bankruptcy petition, insolvency proceeding, or similar proceeding by or  
3 against such Defendant within 14 days of its filing.

4 D. Any submission to the Commission required by this Order to be  
5 sworn under penalty of perjury must be true and accurate and comply with 28  
6 U.S.C. § 1746, such as by concluding: “I declare under penalty of perjury under  
7 the laws of the United States of America that the foregoing is true and correct.  
8 Executed on: \_\_\_\_\_” and supplying the date, signatory’s full name, title (if  
9 applicable), and signature.

10 E. Unless otherwise directed by a Commission representative in writing,  
11 all submissions to the Commission pursuant to this Order must be emailed to  
12 DEbrief@ftc.gov or sent by overnight courier (not the U.S. Postal Service) to:  
13 Associate Director for Enforcement, Bureau of Consumer Protection, Federal  
14 Trade Commission, 600 Pennsylvania Avenue NW, Washington, DC 20580. The  
15 subject line must begin: FTC v. Regenerative Medical Group, Inc., No. \_\_\_\_\_.

16 **XI.**

17 **RECORDKEEPING**

18 **IT IS FURTHER ORDERED** that Defendants must create certain records  
19 for 10 years after entry of the Order, and retain each such record for 5 years.  
20 Specifically, each Defendant, for any business that such Defendant, individually or  
21 collectively with any other Defendants, is a majority owner or controls directly or  
22 indirectly, must create and retain the following records:

23 A. accounting records showing the revenues from all goods or services  
24 sold;

25 B. personnel records showing, for each person providing services,  
26 whether as an employee or otherwise, that person’s: name; addresses; telephone  
27 numbers; job title or position; dates of service; and (if applicable) the reason for  
28 termination;

1 C. records of all consumer complaints and refund requests, whether  
2 received directly or indirectly, such as through a third party, and any response;

3 D. all records necessary to demonstrate full compliance with each  
4 provision of this Order, including all submissions to the Commission; and

5 E. a copy of each unique advertisement or other marketing material.

6 **XII.**

7 **COMPLIANCE MONITORING**

8 **IT IS FURTHER ORDERED** that, for the purpose of monitoring  
9 Defendants' compliance with this Order, and any failure to transfer any assets as  
10 required by this Order:

11 A. Within 14 days of receipt of a written request from a representative of  
12 the Commission, each Defendant must: submit additional compliance reports or  
13 other requested information, which must be sworn under penalty of perjury; appear  
14 for depositions; and produce documents for inspection and copying. The  
15 Commission is also authorized to obtain discovery, without further leave of court,  
16 using any of the procedures prescribed by Federal Rules of Civil Procedure 29, 30  
17 (including telephonic depositions), 31, 33, 34, 36, 45, and 69.

18 B. For matters concerning this Order, the Commission is authorized to  
19 communicate directly with each Defendant. Defendant must permit  
20 representatives of the Commission to interview any employee or other person  
21 affiliated with any Defendant who has agreed to such an interview. The person  
22 interviewed may have counsel present.

23 C. The Commission may use all other lawful means, including posing,  
24 through its representatives as consumers, suppliers, or other individuals or entities,  
25 to Defendants or any individual or entity affiliated with Defendants, without the  
26 necessity of identification or prior notice. Nothing in this Order limits the  
27 Commission's lawful use of compulsory process, pursuant to Sections 9 and 20 of  
28 the FTC Act, 15 U.S.C. §§ 49, 57b-1.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

D. Upon written request from a representative of the Commission, any consumer reporting agency must furnish consumer reports concerning Individual Defendant, pursuant to Section 604(1) of the Fair Credit Reporting Act, 15 U.S.C. §1681b(a)(1).

**XIII.**

**RETENTION OF JURISDICTION**

**IT IS FURTHER ORDERED** that this Court retains jurisdiction of this matter for purposes of construction, modification, and enforcement of this Order.

**SO ORDERED:**



**DATED: October 25, 2018**

---

**United States District Judge  
Andrew J Guilford**

ATTACHMENT A

[On Regenerative Medical Group letterhead]

[on envelope]

**IMPORTANT NOTICE ABOUT COURT SETTLEMENT**

[content of letter, 16-point font]

Dear [Recipient]:

The Federal Trade Commission (FTC), the nation's consumer protection agency, has sued us for deceptive advertising related to our promises that our stem cell therapy treats a variety of serious diseases and health conditions. To settle the lawsuit we have agreed to:

- stop claiming that stem cell therapy treats or cures any disease or health condition, including Parkinson's disease, autism, multiple sclerosis (MS), cerebral palsy, traumatic brain injury, heart disease, macular degeneration, chronic kidney disease, osteoarthritis, and stroke; and
- stop claiming that stem cell therapy is comparable or superior to conventional medical treatments in curing, mitigating, or treating these diseases or health conditions.

The FTC says these claims are not currently backed by competent and reliable scientific evidence. Therefore, we can't make these claims in the future unless they can be supported by scientific proof.

You can find out more about the FTC's lawsuit at [URL].

Sincerely,

[Regenerative Medical Group signatory]